Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Income from Continuing Operations (2016 - 2026)

United Therapeutics' Income from Continuing Operations history spans 17 years, with the latest figure at 364300000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 20.91% to 364300000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1334700000.0, a 11.68% increase, with the full-year FY2025 number at 1334700000.0, up 11.68% from a year prior.
  • Income from Continuing Operations hit 364300000.0 in Q4 2025 for United Therapeutics, up from 338700000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for UTHR hit a ceiling of 364300000.0 in Q4 2025 and a floor of 28300000.0 in Q1 2021.
  • Historically, Income from Continuing Operations has averaged 235885000.0 across 5 years, with a median of 250050000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 79.45% in 2021 and later surged 747.7% in 2022.
  • Tracing UTHR's Income from Continuing Operations over 5 years: stood at 112200000.0 in 2021, then increased by 17.74% to 132100000.0 in 2022, then skyrocketed by 64.35% to 217100000.0 in 2023, then skyrocketed by 38.78% to 301300000.0 in 2024, then grew by 20.91% to 364300000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for UTHR at 364300000.0 in Q4 2025, 338700000.0 in Q3 2025, and 309500000.0 in Q2 2025.